Validation Study of the Korean Version of the EORTC QLQ-HDC29
The aim of this study is to evaluate the reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer High-dose Chemotherapy module (EORTC HDC-29).
Quality of Life After Stem Cell Transplantation
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Quality of Life in Patients With Stem Cell Transplant After High Dose Chemotherapy: Validation Study of the Korean Version of the EORTC QLQ-HDC29|
- Reliability and validity of the Korean version of the EORTC HDC-29 [ Time Frame: at the patient's hospitalization (before the SCT) and the outpatient clinic (three, six, and 12 months after their SCT) ] [ Designated as safety issue: No ]
Relaibility; Cronbach's alpha coefficient is used to evaluate the internal consistency.
Validity; Persons's correlation coefficient is used to examine the correlation between similar dimensions of the different questionnaires.
|Study Start Date:||September 2010|
|Study Completion Date:||December 2013|
|Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01208532
|Korea, Republic of|
|Seoul National University Hospital|
|Seoul, Korea, Republic of|
|Principal Investigator:||Sung-Soo Yoon, MD, PhD||Seoul National University Hospital|
|Principal Investigator:||Jung Mi Oh, Pharm.D.||College of Pharmacy, Seoul National University|